Therapeutic potential of S179D prolactin - From prostate cancer to angioproliferative disorders: The first selective prolactin receptor modulator

Expert Opinion on Investigational Drugs

Volumn 15, Issue 10, 2006, Pages 1257-1267

  Walker, Ameae M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory; Antiangiogenic; Breast cancer; Prolactin; Prostate cancer; S179D prolactin; SPeRM

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; PROLACTIN DERIVATIVE; PROLACTIN RECEPTOR; S 179D; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CELL CYCLE ARREST; CELL DIFFERENTIATION; HUMAN; NONHUMAN; PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TOXICITY TESTING; VASCULAR DISEASE;

ANIMALS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROLACTIN; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN;

EID: 33750234935     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.10.1257     Document Type: Review

References (105)

1. TANSEY MJ, SCHLECTE JA: Pituitary production of prolactin and prolactin-suppressing drugs. Lupus (2001) 10:660-664.
2. BEN-JONATHAN N, LIBY K, McFARLAND M, ZINGER M: Prolactin as an autocrine/ paracrine growth factor in human cancer. Trends Endocrinol. Metab. (2002) 13:245-250.
3. CORBACHO AM, MARTINEZ DE LA ESCALERA G, CLAPP C: Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J. Endocrinol. (2002) 173:219-238.
4. AHONEN TJ, HARKONEN PL, LAINE J, RUI H, MARTIKAINEN PM, NEVALAINEN MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology (1999) 140:5412-5421.
5. VONDERHAAR BK: Protactin involvement in breast cancer. Endocr. Relat. Cancer (1999) 6:389-404.
6. NOWAK RA, MORA S, DIEHL T, RHOADES AR, STEWART EA: Prolactin is an autocrine or paracrine growth factor for human myometriat and leiomyoma cells. Gynecol. Obstet. Invest. (1999) 48:127-132.
7. WOOD RL, ZHANG J, HUANG ZM et al.: Prolactin and prolactin receptors in the lacrimal gland. Exp. Eye Res. (1999) 69:213-226.
8. KROWN KA, WANG YF, WALKER AM: Autocrine interaction between prolactin and its receptor occurs intracellularty in the 235-1 mammotroph cell line. Endocrinology (1994) 134:1546-1552.
9. KROWN KA, WANG YF, HO TW, KELLY PA, WALKER AM: Prolactin isoform 2 as an autocrine growth factor for GH3 cells. Endocrinology (1992) 131:595-602.
10. NEVALAINEN MT, VALVE EM, INGLETON PM, NURMI M, MARTIKAINEN PM, HARKONEN PL: Prolactin and prolactin receptors are expressed and functioning in human prostare. J. Clin. Invest. (1997) 99:618-627.
11. MATERA L, CUTUFIA M, GEUNA M et al.: Prolactin is an autocrine growth factor for the Jurkat human T-leukemia cell line. J. Neuroimmunol. (1997) 79:12-21.
12. PELLEGRINI I, LEBRUN JJ, ALI S, KELLY PA: Expression of prolactin and its receptor in human lymphoid cells. Mol. Endocrinol. (1992) 6:1023-1031.
13. GUTZMAN JH, MILLER KK, SCHULER LA: Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor α and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid Biochem. Mol. Biol. (2004) 88:69-77.
14. ROSE-HELLEKANT TA, ARENDT LM, SCHROEDER MD, GILCHRIST K, SANDGREN EP, SCHULER LA: Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene (2003) 22:4664-4674.
15. DILLNER K, KINDBLOM J, FLORES-MORALES A et al.: Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology (2003) 144:4955-4966.
16. KINDBLOM J, DILLNER K, SAHLIN L et al.: Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology (2003) 144:2269-2278.
17. XU X, KREYE E, KUO CB, WALKER AM: A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res. (2001) 61:6098-6104.
18. CLEVENGER CV, FURTH PA, HANKINSON SE, SCHULER LA: The role of prolactin in mammary carcinoma. Endocr. Rev. (2003) 24:1-27.
19. NEVILLE MC, McFADDEN TB, FORSYTH I: Hormonal regulation of mammary differentiation and milk secretion. J. Mammary Gland Biol Neoplasia (2002) 7:49-66.
20. GOFFIN V, BINART N, TOURAINE P. KELLY PA: Prolactin: the new biology of an old hormone. Ann. Rev. Physiol. (2002) 64:47-67.
21. BEN-JONATHAN N, MERSHON JL, ALLEN DL, STEINMETZ RW: Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev. (1996) 17:639-669.
22. ZINGER M, McFARLAND M, BEN-JONATHAN N: Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab. (2003) 88:689-696.
23. BELLONE G, ASTARITA P, ARTUSIO E et al.: Bone marrow stroma-derived prolactin is involved in basal and platelet-activating factor-stimulated in vitro erythropoiesis. Blood (1997) 90:21-27.
24. RICHARDS RG, BRAR AK, FRANK GR, HARTMAN SM, JIKIHARA H: Fibroblast cells from term human deciduas closely resemble endometrial stromal cells: induction of prolactin and insulin-like growth factor binding protein-1 expression. Biol. Reprod. (1995) 52:609-615.
25. PERKS CM, KEITH AJ, GOODHEW KL, SAVAGE PB, WINTERS ZE, HOLLY JM: Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer (2004) 91:305-311.
26. PEIRCE SK, CHEN WY: Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene (2004) 23:1248-1255.
27. SCHROEDER MD, BROCKMAN JL, WALKER AM, SCHULER LA: Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology (2003) 144:5399-5407.
28. ACOSTA JJ, MUNOZ RM, GONZALEZ L et al.: Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erkl/2 and phosphatidylinositol 3-kinase pathways. Mol. Endocrinol. (2003) 17:2268-2282.
29. KACZMARSKI RS, MUFTI GJ: The cytokine receptor superfamily. Blood Rev. (1991) 5:193-203.
30. BERWAER M, MARTIAL JA, DAVIS JR: Characterization of an upstream promoter directing extrapituitary expression of the human prolactin gene. Mol. Endocrinol. (1994) 8:635-642.
31. GELLERSEN B, KENPF R, TELGMANN R, DiMATTIA GE: Nonpituitary human prolactin gene transcription is independent of Pit 1 and differentially controlled in lymphocytes and in endometrial stroma. Mol. Endocrinol. (1994) 8:356-373.
32. WALKER AM: Prolactin receptor antagonists. Curr. Opin. Invest. Drugs (2005) 6:378-385.
33. GOFFIN V, BERNICHTEIN S, TOURAINE P, KELLY PA: Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev, (2005) 26:400-422.
34. WU W, GINSBURG E, VONDERHAAR BK, WALKER AM: S179D prolactin increases vitamin D receptor and p21 through upregulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. (2005) 65:7509-7515.
35. WU W, CHEN YH, UEDA E, TAN D, BARTOLINI P, WALKER AM: Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol. Res. (2006) 16(2):75-84.
36. XU X, WU W, WILLIAMS V et al: Opposite effects of unmodified prolactin on morphology and the expression of prostate-specific genes in the normal rat prostate. Prostate (2002) 54:1-9.
37. WU W, COSS D, LORENSON MY, KUO CB, XU X, WALKER AM: Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry (2003) 42:7561-7570.
38. KUO CB, WU W, XU X et al.: Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes β-casein gene expression in the rat mammary gland. Cell Tissue Res. (2002) 309:429-437.
39. UEDA E, OZERDEM U, CHEN YH et al.: A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer (2006) 13:95-111.
40. UEDA E, LO H-L, BARTOLINI P, WALKER AM: S179D prolactin (PRL) primarily uses the extrinsic pathway and MAP kinase signaling to induce apoptosis in human endothelial cells. Endocrinology (2006) (In Press).
41. YANG L, LII S, KUO B et al.: Maternal prolactin composition can permanently affect epidermal γδT cell function in the offspring. Dev. Compar. Immunol. (2002) 26:849-860.
42. YAN L, KUO CB, LIU Y et al.: Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. J. Endocrinol. (2001) 168:227-238.
43. COSS D, KUO C-YB, YANG L, INGLETON P, LUBEN R, WALKER AM: Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology (1999) 140:5087-5094.
44. WANG Y-F, WALKER AM: Dephosphorylation of standard prolactin produces a more biologically active molecule. Evidence for antagonism between non-phosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. Endocrinology (1993) 133:2156-2160.
45. NAYLOR MJ, OAKES SR, GARDINER-GARDEN M et al.: Transcriptional changes underlying the secretory activation phase of mammary gland development. Mol. Endocrinol. (2005)19:1868-1883.
46. HATTORI N, IKEKUBO K, NAKAYA Y, KITAGAWA K, INAGAKI C: Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J. Clin. Endocrinol. Metab. (2005) 90:3036-3044.
47. WALKER AM: Phosphorylated and non-phosphorylated prolactin isoforms. Trends Endo. Metab. (1994) 5:195-200.
48. HO TWC, LEONG F-S, OLASO CH, WALKER AM: Secretion of specific non-phosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle. Neuroendocrinology (1993) 58:160-165.
49. HO TWC, KAWAMINAMI M, WALKER AM: Secretion of phosphorylated and non-phosphorylated monomer prolactin isoforms during rat pregnancy and pseudopregnancy. Endocrine (1993) 1:435-439.
50. LORENSON MY, JACOBS LS: Thiol regulation of protein, growth hormone, and prolactin release from isolated adenohypophyseal secretory granules. Endocrinology (1982) 110:1164-1172.
51. GREENAN JR, BALDEN E, HO TWC, WALKER AM: Biosynthesis of the secreted 24 kd isoforms of prolactin. Endocrinology (1989) 125:2041-2048.
52. WICKS JR, BROOKS CL: Prolactin kinase activity in bovine anterior pituitary sub-cellular fractions. Mol. Cell Endocrinol. (1999) 147:125-132.
53. TUAZON PT, LORENSON MY, WALKER AM, TRAUGH JA: p21-activated protein kinase γ-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Lett. (2002) 515:84-88.
54. WANG Y-F, LIU J-W, MAMIDI M, WALKER AM: Identification of the major site of rat prolactin phosphorylation as serine 177. J. Biol. Chem. (1996) 271:2462-2469.
55. CHEN TJ, KUO C-YB, TSAI KF, LIU J-W. CHEN D-Y, WALKER AM: Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology (1998) 139:609-616.
56. TAN D, JOHNSON DA, WU W et al.: Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short PRL receptors in living human cells. Mol. Endocrinol. (2005) 19:1291-1303.
57. SEUBERT N, ROYER Y, STAERK J et al.: Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin dimer. Mol. Cell (2003) 12:1239-1250.
58. LEWIS MD, HORAN M, MILLAR DS et al.: A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J. Clin. Endocrinol. Metab. (2004) 89:1068-1075.
59. COSTELLO LC, FRANKLIN RB: Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm. Metab. Res. (2002) 34:417-424.
60. STATTIN P, RINALDI S, STENMAN UH et al.: Plasma prolactin and prostate cancer risk: a prospective study. Int. J. Cancer (2001) 92:463-465.
61. ODOMA S, CHISHOLM GD, NICOL K, HABIB FK: Evidence for the association between blood prolactin and androgen receptor in BPH. J. Urol. (1985) 133:717-720.
62. SAROFF J, KRIDANI RY, CHU M, WAYSANAR Z, MURPHY GP: Measurements of prolactin and androgen in patients with prostatic diseases. Oncology (1980) 37:46-57.
63. GRIFFITHS K: Plasma steroid and protein hormone concentration in patients with prostatic carcinoma before and during oestrogen therapy. Acta Endocrinol. (1976) 81:409-426.
64. LISSONI P, VIGANO P, VAGHI M et al.: A Phase II study of tamoxifen in hormone resistant metastatic prostate cancer: a possible relation with prolactin secretion. Anti-Cancer Res. (2005) 25:3597-3599.
65. LISSONI P, BIGNAMI A, FRONTINI L et al.: Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. Int. J. Biol. Markers (2005) 20:123-125.
66. LEAV I, MERK FB, LEE KF et al.: Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am. J. Pathol. (1999) 154:863-870.
67. WENNBO H, KINDBLOM J, ISAKSSON OGP, TORNELL J: Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology (1997) 138:4410-4415.
68. DILLNER K, KINDBLOM J, FLORES-MORALES A et al.: Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology (2003) 144:4955-4966.
69. KINDBLOM J, DILLNER K, SAHLIN L et al.: Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology (2003) 144:2269-2278.
70. ROBERTSON FG, HARRIS J, NAYLOR MJ et al.: Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology (2003) 144:3196-3205.
71. WU W, WALKER AM: Dual treatment possibilities with S179D prolactin and physiological levels of 1,25 dihydroxy vitamin D3. American Association for Cancer Research Annual Meeting, Washington DC, USA (1 - 5 April 2006) (Abstract 4870).
72. JOHNSON TE, VUE M, BREKHUS S, KHONG A, HO TWC, WALKER AM: Unmodified prolactin (PRL) promotes PRL secretion and acidophil hypertrophy and is associated with pituitary hyperplasia in female rats. Endocrine (2003) 20:101-110.
73. UTAMA FE, LEBARON MJ, NEILSON LM et al.: Human prolactin receptors are insensitive to mouse prolactin: implications for xenotranslant modeling of human breast cancer in mice. J. Endocrinol. (2006) 188:589-601.
74. GUZMAN EA, CHEN YH, LANGOWSKI JL et al.: Abrogation of delayed type hypersensitivity responses to candida albicans produced by a molecular mimic of phosphorylated prolactin. J. Neuroimmunol. (2005)170:31-40.
75. PALAPATTU GS, SUTCLIFFE S, BASTIAN PJ et al.: Prostate carcinogenesis and inflammation:emerging insights. Carcinogenesis (2005) 26:1170-1181.
76. HLATKY L, HAHNFELDT, P, FOLKMAN J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. (2002) 94:883-893.
77. FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1:27-31.
78. OZERDEM U: Targeting neovascular pericytes in neurofibromatosis type 1. Angiogenesis (2004) 7:307-311.
79. MANNELLO F, TONTI G, PAPA S: Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets (2005) 5:285-298.
80. PORTER JF, SHARMA S, WILSON DL, KAPPIL MA, HART RP, DENHART DT: Tissue inhibitor of metalloproteinases-1 stimulates gene expression in MDA-MB-435 human breast cancer cells by means of its ability to inhibit metalloproteases. Breast Cancer Res. Treat. (2005) 94:185-193.
81. SCAFFIDI C, FULDA S, SRINIVASAN A et al.: Two CD95 (Apo-1/Fas) signaling pathways. EMBO J. (1998) 17:1675-1687.
82. TWOROGER SS, HANKINSON SE: Prolactin and breast cancer risk. Cancer Lett. (2006) (In Press).
83. TOURAINE P, MARTINI JF, ZAFRANI B et al.: Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. (1998) 83:667-674.
84. REYNOLDS C, MONTONE KT, POWELL CM, TOMASZEWSKI JE, CLEVENGER CV: Expression of prolactin and its receptor in human breast carcinoma. Endocrinology (1997) 138:5555-5560.
85. GILL S, PESTON D, VONDERHAAR BK, SHOUSHA S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J. Clin. Pathol. (2001) 54:956-960.
86. VOMACHKA AJ, PRATT SL, LOCKEFEERJA, HORSEMAN ND: Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene (2000) 19:1077-1084.
87. WENNBO H, GEBRE-MEDHIN M, GRITLI-LINDE A, OHLSSON C, ISAKSSON OG, TORNELL J: Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. (1997) 100:2744-2751.
88. CLEVENGER CV, FURTH PA, HANKINSON SE, SCHULER LA: The role of prolactin in mammary carcinoma. Endocr. Rev. (2003) 24:1-27.
89. SULTAN AS, XIE J, LE BARON MJ, EALLEY EL, NEVALAINEN MT, RUI H: Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 24:746-760.
90. NOUHI Z, CHUGHTAI N, HARTLEY S, COCLAKIS E, LEBRUN JJ, ALI S: Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. (2006) 66:1824-1832.
91. WU W, DENG C, BROCKMAN JL, LUBEN R, SCHULER LA, WALKER AM: Superior stimulation of β-casein mRNA accumulation by pseudophosphorylated prolactin (S179D PRL) is a consequence of both enhanced transcription and message stabilization. (2006) (Submitted manuscript).
92. WALKER SE: Bromocryptine treatment of systemic lupus erythematosus. Lupus (2001) 10:762-768.
93. WALKER SE, YANG L, KUO CB, WALKER AM: A pilot study suggests that prolactin shortens, and a prolactin receptor antagonist lengthens, the life span of NZB/NZW mice with spontaneous lupus erythematosus. Endocrine Society Annual Meeting, San Diego, USA (12 - 15 June 1999) (Abstract P2-171).
94. GILLERAN JP, PUTZ O, DEJONG M et al.: The role of prolactin in the prostatic inflammatory response to neonatal estrogen. Endocrinology (2003) 144:2046-2054.
95. GOFFIN V, BERNICHTEIN S, KAYSER C, KELLY PA: Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary (2003) 6:89-95.
96. LANGENHEIM JF, CHEN WY: Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res. Treat. (2005) 90:281-293.
97. BECK MT, CHEN NY, FRANEK KJ, CHEN WY: Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. (2003) 63:3598-3604
98. SOARES CRJ, GLEZER A, OKAZAKI K et al.: Physico-chemical and biological characterizations of two human prolactin analogs exhibiting controversial bioactivity, synthesized in Chinese hamster ovary (CHO) cells. Protein Expr. Purif. (2006) 48:182-194.
99. BERNICHTEIN S, KINET S, JEAY S et al.: S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not antagonist. Endocrinology (2001) 142:3950-3963.
100. BRIDGES R, RIGERO B, BYRNES E, YANG L, WALKER A: Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Endocrinology (2001) 142:730-739.
101. BERNICHTEIN S, KAYSER C, DILLNER K et al.: Development of pure prolactin receptor antagonists. J. Biol. Chem. (2003) 278:35988-35999.
102. KLINE JB, CLEVENGER CV: Identification and characterization of the prolactin-binding protein in human serum and milk. J. Biol. Chem. (2001) 276:24760-24766.
103. BRODY S, KRUGER TH: The post-orgasmic prolactin increase following intercourse is greater than following masturbation and suggests greater satiety. Biol. Psychol. (2006) 71:312-315.
104. BUDGE H, MOSTYN A, WILSON V et al.: The effect of maternal prolactin infusion during pregnancy on fetal adipose tissue development. J. Endocrinol. (2002) 174:427-433.
105. PEARCE S, BUDGE H, MOSTYN A et al.: Prolactin, the prolactin receptor and uncoupling protein abundance and function in adipose tissue during development in young sheep. J. Endocrinol. (2005) 184:351-359.